<DOC>
	<DOC>NCT00831454</DOC>
	<brief_summary>The aim of this study was to retrospectively evaluate associations between EGFR and AKT DNA-polymorphisms involved in transcriptional regulation and overall survival in NSCLC patients treated with EGFR-TKIs.</brief_summary>
	<brief_title>Identification of EGFR-TKIs Sensitivity or Resistance Markers in NSCLC May Help in Optimal Patient Selection</brief_title>
	<detailed_description>DNA will be isolated from blood samples or paraffin-embedded tumor specimens and than a mutation analysis and SNPs genotyping will be done.</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<criteria>Availability of tumor tissue or blood samples. Diagnosis of NSCLC At least one treatment with EGFRTKIs inhibitors Other than NSCLC primary diagnosis No treatment with EGFRTKIs inhibitors No archival tissue available</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>